InterVenn Company
InterVenn unlocks the glycoproteome using artificial intelligence for the development of transformational healthcare solutions in DX and Rx.
Investors
Technology:
Other
Industry:
AI, P4 Medicine, United States
Headquarters:
South San Francisco, California, United States
Founded Date:
01.03.2017
Employees Number:
101-250
Funding Status:
Late Stage Venture
Investors Number:
13
Total Funding:
2,78E+08
Estimated Revenue:
$1M to $10M
Last Funding Date:
02.08.2021
Last Funding Type:
Series C
Register and Claim Ownership